The Chinese government has kickstarted a new round of a national drug hunting campaign involving the industry and academia, with the first two programs in lung and breast cancer launched this month.
Key Takeaways
- A new China government R&D support program will focus on four major chronic disease areas with high prevalence in China – cardiovascular, respiratory and metabolic diseases and malignant tumors.
Th fresh state-supported effort will be focused primarily on four major chronic conditions with a high prevalence in China –...
Welcome to Scrip
Create an account to read this article
Already a subscriber?